NCT04895566View on ClinicalTrials.gov

Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

March 10, 2023

Study Completion Date

March 16, 2023

Conditions
PyodermaPyoderma GangrenosumPyoderma VegetansPyoderma Gangrenosum Surrounding Surgical Stoma
Interventions
BIOLOGICAL

Monoclonal antibody (Mab) sB24M

200 mg monoclonal antibody (Mab) sB24 by injection into the affected areas.

Trial Locations (2)

12001

Contract Research Organization, Minsk

LV-1079

Contract Research Organization, Riga

All Listed Sponsors
lead

SWISS BIOPHARMA MED GmbH

OTHER